RT Journal Article
T1 Somatic mutations in tumor and plasma of locoregional recurrent and/or metastatic head and neck cancer using a next-generation sequencing panel: A preliminary study
A1 Rapado González, Óscar
A1 Brea Iglesias, Jenifer
A1 Rodríguez Casanova, Aitor
A1 Bao Caamaño, Aida
A1 López Cedrún, José Luis
A1 Triana Martínez, Gabriel
A1 Díaz Peña, Roberto
A1 Arminda Santos, María
A1 López López, Rafael
A1 Muinelo Romay, Laura
A1 Martínez Fernández, Mónica
A1 Díaz Lagares, Ángel
A1 Suárez Cunqueiro, María Mercedes
K1 Cell-free DNA
K1 Droplet digital PCR
K1 Head and neck squamous cell carcinoma
K1 Liquid biopsy
K1 Next-generation sequencing
K1 Saliva
K1 Somatic mutations
AB BackgroundWe explore the utility of TruSight Tumor 170 panel (TST170) for detecting somatic mutations in tumor and cfDNA from locoregional recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC).MethodsTargeted NGS of tumor DNA and plasma cfDNA was performed using TST170 panel. In addition, a set of somatic mutations previously described in HNSCC were selected for validating in tumor, plasma, and saliva by digital droplet PCR.ResultsThe TST170 panel identified 13 non-synonymous somatic mutations, of which five were detected in tumoral tissue, other five in plasma cfDNA, and three in both tissue and plasma cfDNA. Of the eight somatic mutations identified in tissue, three were also identified in plasma cfDNA, showing an overall concordance rate of 37.5%.ConclusionsThis preliminary study shows the possibility to detect somatic mutations in tumor and plasma of HNSCC patients using a single assay that would facilitate the clinical implementation of personalized medicine in the clinic
PB Wiley
SN 2045-7634
YR 2022
FD 2022-11-24
LK https://hdl.handle.net/10347/38745
UL https://hdl.handle.net/10347/38745
LA eng
NO Rapado-González Ó, Brea-Iglesias J, Rodríguez-Casanova A, et al. Somatic mutations in tumor and plasma of locoregional recurrent and/or metastatic head and neck cancer using a next-generation sequencing panel: A preliminary study. Cancer Med. 2023;12:6615-6622. doi:10.1002/cam4.5436
DS Minerva
RD 22 abr 2026